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Proteins are often made in more than one form, with alternate versions sometimes residing in different cellular
compartments than the primary species. The mammalian prion protein (PrP), a cell surface GPI-anchored protein, is a
particularly noteworthy example for which minor cytosolic and transmembrane forms have been implicated in disease
pathogenesis. To study these minor species, we used a selective labeling strategy in which spatially restricted expression
of a biotinylating enzyme was combined with asymmetric engineering of the cognate acceptor sequence into PrP. Using
this method, we could show that even wild-type PrP generates small amounts of the CtmPrP transmembrane form.
Selective detection of CtmPrP allowed us to reveal its N-terminal processing, long half-life, residence in both intracellular
and cell surface locations, and eventual degradation in the lysosome. Surprisingly, some human disease-causing mutants
in PrP selectively stabilized CtmPrP, revealing a previously unanticipated mechanism of CtmPrP up-regulation that may
contribute to disease. Thus, spatiotemporal tagging has uncovered novel aspects of normal and mutant PrP metabolism
and should be readily applicable to the analysis of minor topologic isoforms of other proteins.
INTRODUCTION
A characteristic feature of complex organisms is their ability
to markedly diversify the protein products generated from a
comparatively small number of genetic elements. Through
the use of alternative promoter usage, alternative splicing,
translational regulation, modiﬁcation, processing, regulated
degradation, and trafﬁcking, a single gene may generate any
of numerous potential protein products in a highly context
dependent manner. While the major protein product is typ-
ically the most extensively studied, it is increasingly appre-
ciated that minor or transiently generated alternative protein
species often have critical functional roles.
For example, many proteins are primarily made and re-
side in an inactive form, with the active form represented by
minor or transiently produced products. Hence, the minor
species of key factors like steroid hormone receptors (Yudt
and Cidlowski, 2002), membrane-bound transcription fac-
tors (Sannerud and Annaert, 2009), or caspases (Pop and
Salvesen, 2009) are in fact the primary functional product.
Even seemingly artifactual minor truncated versions of
Glucocorticoid receptor resulting from internal transla-
tion initiation seem to be physiologically relevant func-
tional products in vivo (Lu and Cidlowski, 2005; Lu et al.,
2007). Thus, understanding the nuances and regulation of
complex organism physiology will require an understand-
ing of not only how proteomic complexity is generated,
but the functional roles of the various major and minor
products.
However, studying the alternative minor species of a protein
often poses several technical obstacles depending on its com-
parative abundance and difference from the major species. In
the simplest case, the minor species can be differentiated on the
basis of a unique sequence element (e.g., generated by an
isoform-speciﬁc exon) that can be immunologically detected
with high speciﬁcity and sensitivity. However, this is not
always possible. For example, alternative forms generated
via facultative translocation or trafﬁcking can generate mi-
nor variants whose main distinguishing feature is its alter-
native cellular location.
Indeed, proteins with targeting signals for the ER, mito-
chondria, peroxisomes, and chloroplasts can potentially re-
side in the cytosol as a minor (or ‘eclipsed’) nontranslocated
form (reviewed by Regev-Rudzki and Pines, 2007). While
this is sometimes apparently attributable to errors (Anan-
datheerthavarada et al., 2003; Drisaldi et al., 2003; Rane et al.,
2004; Levine et al., 2005), numerous examples have been
described where the noncompartmentalized form has a
function (see Yogev et al., 2010, for an especially compelling
recent example). This species can be generated by alternative
splice variants that lack the targeting signal (Tong et al.,
2003), alternative translation initiation sites downstream of
the targeting signal (Land and Rouault, 1998; Goulet et al.,
2004), modiﬁcations or processing close to the targeting
signal (Addya et al., 1997; Robin et al., 2002; Colombo et al.,
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43252005; Dasari et al., 2006; Boopathi et al., 2008), or just intrinsic
inefﬁciencies in the targeting or translocation process (Stein
et al., 1994; Sass et al., 2001; Shaffer et al., 2005; Regev-Rudzki
et al., 2005; Naamati et al., 2009; Matthews et al., 2010).
Studying these minor, differentially compartmentalized, and
often transiently generated species has been challenging.
Yet, they are nonetheless important. In cases where they
represent mistakes, their quality control and degradation is
likely to help maintain protein homeostasis in the cytosol. In
cases where they have functional relevance, delineating their
function requires their selective identiﬁcation and analysis.
One example where alternative species are thought to be
important is mammalian Prion protein (PrP). While the
function of this widely expressed cell surface GPI-anchored
glycoprotein remains to be clearly elucidated (Westergard et
al., 2007; Aguzzi et al., 2008), it is best known for causing
various fatal neurodegenerative diseases when misfolded in
certain ways (Prusiner, 1998; Aguzzi and Calella, 2009).
Recently, several cell biological studies have focused on the
possibility that mislocalization of PrP can be detrimental to
the cell and perhaps be a contributing factor in the patho-
genesis of at least some of the associated diseases (reviewed
in Chakrabarti et al., 2009). One source of PrP mislocalization
stems from a slight inefﬁciency in the function of its N-
terminal signal sequence (Kim et al., 2002; Rane et al., 2004;
Levine et al., 2005). This typically results in 10% failed
translocation into the ER (Rane et al., 2004; Levine et al.,
2005), generating a minor cytosolic form of PrP termed
cyPrP (Ma and Lindquist, 2002; Drisaldi et al., 2003; Rane et
al., 2004). However, signal sequence inefﬁciency can have
another outcome. If, after targeting to the translocon, the
signal sequence fails to initiate translocation of the N termi-
nus, an internal hydrophobic domain (HD, at residues
112–135) can engage the translocon and direct membrane
insertion of PrP (Kim et al., 2001; Kim et al., 2002; Kim and
Hegde, 2002; see Supplemental Figure S1). This transmem-
brane form, termed CtmPrP, has the N terminus in the cy-
tosol and C terminus in the ER lumen (Hegde et al., 1998).
Importantly, mutations that increase hydrophobicity of the
hydrophobic domain result in increased CtmPrP production
(Hegde et al., 1998; Kim et al., 2001; Stewart and Harris, 2001,
2003).
Studies in transgenic mice manipulating PrP translocation
in several ways have illustrated that increased generation of
either cyPrP or CtmPrP can cause neurodegeneration (Hegde
et al., 1998, 1999; Ma et al., 2002; Stewart et al., 2005; Rane et
al., 2008). Of note, several human disease mutations are in
the central hydrophobic domain that, based on in vitro
assays, result in increased CtmPrP (Hegde et al., 1998; Stewart
and Harris, 2001; Kim and Hegde, 2002; Rane et al., 2010).
One of these, A117V, has also been modeled in transgenic
mice and shown to cause a late-onset neurodegeneration
(Hegde et al., 1999; Yang et al., 2009; Rane et al., 2010) and
increased CtmPrP (Hegde et al., 1999; Rane et al., 2010). As
predicted from the above description of how cyPrP and
CtmPrP are generated, improving signal sequence efﬁciency
resulted in reduced generation of these forms in vitro (Kim
and Hegde, 2002) and in transgenic mice (Rane et al., 2010),
and rescued mice from neurodegeneration (Rane et al., 2010).
Thus, CtmPrP and cyPrP, while minor species of PrP, may be
of considerable importance to the pathogenesis of at least
some diseases. However, these forms, particularly CtmPrP,
are especially difﬁcult to detect and follow in biochemical
analyses, and this has severely limited insights into its bio-
synthesis, trafﬁcking, and metabolism.
The difﬁculty in detecting and analyzing the minor cyPrP
and CtmPrP forms is primarily an issue of signal to noise. In
the case of CtmPrP, the polypeptide is identical (or nearly so)
to the major fully translocated species: both are glycosylated
and GPI-anchored, migrate similarly on SDS-PAGE, and are
composed of the same polypeptide sequence (Hegde et al.,
1998; Stewart et al., 2001; Kim and Hegde, 2002; Stewart and
Harris, 2003). Thus, selective antibody detection is difﬁcult.
While conformation-speciﬁc antibodies are a theoretical pos-
sibility, this poses substantial technical hurdles given that
the speciﬁc conformations are not easy to generate in high
amounts as a source of antigens. Thus, to study CtmPrP, a
method to selectively mark this minor species is needed.
Here we have explored the possibility of using compart-
ment-restricted and site-speciﬁc biotinylation as a method
for selective tagging of CtmPrP. We characterize this method
for use in mammalian cells and use it to delineate basic but
key features of CtmPrP biosynthesis and metabolism. Illus-
trating the power of this approach, we show that, unexpect-
edly, CtmPrP metabolism is selectively perturbed by disease-
associated mutants in PrP previously unknown to affect PrP
topology.
MATERIALS AND METHODS
DNA Constructs
Wild-type Hamster PrP and the various derivatives from it [SS-PrP, SA-PrP,
Prl-PrP, PrP(G123P), PrP(AV3), Prl-PrP(G123P)] have been described (Hegde
et al., 1998; Kim et al., 2002; Rane et al., 2004; Chakrabarti and Hegde, 2009).
Wild-type Human PrP and its various disease-associated point mutants have
been described (Ashok and Hegde, 2009). In each case, the BioTag or an HA
epitope tag was inserted using synthetic oligos into the unique Bsu36I site at
codon 50. Both epitopes were ﬂanked by an Alanine on both sides. BirA was
cloned by PCR from total E. coli K-12 DNA. An N-terminal FLAG tag was
incorporated into the 5 primer and the product inserted by standard methods
into a mammalian (pCDNA3.1-based) expression vector. BirA for bacterial
expression lacked the FLAG tag and was inserted into the His-tag containing
pRSET-A vector. SS-BirA-KDEL was made by PCR amplifying the BirA open
reading frame with the FLAG epitope and KDEL signal encoded in the 5 and
3 primers, respectively, and ligating to a mammalian expression plasmid
containing the Prl signal sequence (Kim et al., 2002). For the purposes of
topology analysis, we have not observed any differences between Hamster
PrP and Human PrP. Human PrP was used in all of the experiments shown
except in Figure 1 and Figure 2, where Hamster constructs were used.
Antibodies
Anti-PrP antibodies used in this study were either PrP-A, a rabbit polyclonal
against the PrP N terminus from residues 23–38 (Ashok and Hegde, 2008;
Rane et al., 2008), or 3F4 (Covance, Princeton, NJ), a mouse monoclonal whose
epitope is at residues 109–112. PrP-A recognizes all mammalian species of PrP
and the SA-PrP construct. 3F4 recognizes Hamster and Human PrP, but not
SA-PrP. These were used interchangeably with indistinguishable results,
except in experiments with SA-PrP, in which case PrP-A was used. The
TRAP antibody has been described (Fons et al., 2003).
Cell Culture
Unless otherwise indicated, all experiments were performed in Neuro 2a
(N2a) cells obtained from ATCC. Key results were conﬁrmed to be reproduc-
ible in HeLa, HEK293, and HT1080 cells (unpublished results). To facilitate
much of the routine characterization, N2a cells stably expressing BirA were
produced by isolating and selecting for clones from single cells using stan-
dard methods. However, transient cotransfection with BirA produced iden-
tical results and stable expression was not essential. In instances where BirA
was cotransfected, it occupied between one-sixth and one-ﬁfth of the total
DNA. Transfection was with either Lipofectamine 2000 or Effectene with
similar results. Cells were assayed between 24 and 48 h after transfection. In
nearly all experiments, a small amount (typically one-ﬁfth of the total amount
of the DNA) of a CFP or GFP expression plasmid was cotransfected to verify
that efﬁciency of transfection was at least 70%. Although not shown, this was
often used as an expression control. Experiments were typically performed on
cells at 70–90% conﬂuent. Pulse-chase studies were performed on cells in
six-well dishes as described (Rane et al., 2004; Ashok and Hegde, 2008; Ashok
and Hegde, 2009). Although adding exogenous biotin to the media was not
absolutely necessary, the experiments here contained 10 uM biotin in the
culture media that was typically added at the time of transfection.
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In vitro transcription, translation in reticulocyte lysate, and translocation
using canine pancreatic rough microsomes has been described (Kim et al.,
2002; Fons et al., 2003; Sharma et al., 2010). The protease protection assay for
topology was as before (Kim et al., 2002). For biotinylation, translation reac-
tions were placed on ice and recombinant BirA added to a ﬁnal concentration
of 50 ng/ul, which was determined in preliminary experiments to be the
lowest concentration needed to give saturating biotinylation. Biotin was
added to 50 uM, and the reaction was allowed to proceed on ice for 1 h.
Experiments at various temperatures showed that higher temperatures were
unnecessary and provided no additional modiﬁcation. The reaction was then
placed onto a sucrose cushion (of 0.5 M sucrose in PSB: 100 mM KAc, 50 mM
HEPES, pH 7.4, 2 mM MgAc2) and the microsomes isolated by sedimentation
(Kim et al., 2002). This was necessary to remove the free biotin, which
otherwise competed in the subsequent avidin pulldown. The microsomes
were solubilized in 1% SDS, 0.1M Tris, pH 8, denatured by boiling, diluted
10-fold in IP buffer (1% Triton X-100, 50 mM HEPES, pH 7.4, 100 mM NaCl),
and incubated with 10 l (packed volume) of immobilized Avidin (Pierce)
that was prewashed in IP buffer. After incubation for 2 h with end-over-end
rotation, the beads were washed three times in IP buffer and the bound
products eluted by boiling in SDS-PAGE sample buffer.
Analysis of Biotinylated Products from Cells
For most analyses (unless speciﬁcally indicated), cells were washed twice in
PBS and lysed by addition of 1% SDS, 0.1 M Tris, pH 8.0, and immediately
denatured by boiling. The DNA was sheared by repeated boiling and vor-
texing until the viscosity was reduced. Typically, one well of a six-well dish
was harvested in 150 l. This method of rapid denaturation ensured that no
post-lysis biotinylation could occur, as was conﬁrmed by mixing experiments
(Supplemental Figure S3). Almost all experiments used this strategy, except
where detergent solubility of PrP products was being examined (e.g., Figure
7, A and E). In this case, cells were washed in PBS and lysed in ice-cold
detergent buffer (typically 1 ml per well of a six-well dish) composed of 100
mM NaCl, 50 mM HEPES, pH 7.5, 0.5% Triton X-100, 0.5% Deoxycholate.
Again, mixing experiments veriﬁed that under these conditions, post-lysis
biotinylation was not detectable in the time frame of our experiments. These
samples were then homogenized by repeated pipetting and/or passage
through 23–25 gauge needles, and spun at maximum speed in a cold-room
microfuge for 30 min. The supernatant and pellet were then solubilized in
SDS-PAGE sample buffer. For avidin pulldowns, samples were adjusted with
IP buffer to reduce the SDS concentration to 0.1%. Any insoluble material was
sedimented for 10 min in a microfuge, and the supernatant incubated for 1 h
at 4°C with plain sepharose beads to pre-clear the lysate. The supernatant
from this pre-clearing step was then incubated with avidin-agarose (10 l,
pre-equilibrated in IP buffer) for 2 h at 4°C with constant mixing. The beads
were washed four times in IP buffer, once in IP buffer containing 2 M urea (to
reduce background), and eluted in SDS-PAGE sample buffer by boiling.
Avidin blots used Avidin-HRP, using biotin-free puriﬁed BSA (3%) as a
blocking reagent. Preliminary experiments were used to identify the optimal
dilution of the Avidin-HRP to minimize background. To verify that recovery
was uniform in all of the avidin pulldown samples (e.g., in a pulse-chase),
each sample was spiked before the pulldown with a known quantity (typi-
cally 1 g) of biotinylated BSA. This was insufﬁcient to compete for binding
to the beads but allowed conﬁrmation of equal recovery and loading of all
samples upon coomassie staining of the gel.
Analysis of CtmPrP N-Terminal Processing
Cells in a six-well dish were pulse-labeled for 30 min with [35S]methionine
(Ashok and Hegde, 2008) and harvested in denaturing conditions with 1%
SDS, 0.1M Tris, pH 8. After boiling the sample, the material from three wells
were pooled and diluted 10-fold in IP buffer. This was incubated with 100 l
of packed ConA-sepharose for 1.5 h with constant gentle mixing. The beads
were washed twice in IP buffer and twice with IP buffer containing 0.5 M
NaCl. The washed beads were resuspended in TEV digestion buffer (as per
the manufacturer’s directions) and incubated with TEV protease overnight at
4°C. The released products were separated from the beads and subjected to
pulldown with Avidin-sepharose as above. The ﬁnal products were analyzed
by SDS-PAGE next to in vitro translated markers. To generate these markers,
the relevant region of the PrPBio/TEV construct was PCR ampliﬁed with
primers encoding an SP6 promoter in the 5 primer and stop codon in the 3
primer. The PCR product was then translated in reticulocyte lysate (Sharma
et al., 2010). As a positive control to monitor the TEV digestion reaction, the
above steps were performed but using immobilized anti-PrP antibodies
(the 3F4 monoclonal; Covance) instead of ConA. After the digestion reac-
tion on the IP samples, SDS-PAGE sample buffer was added and the total
products analyzed directly.
Miscellaneous Biochemistry
Immobilized ConA was from GE Biosciences (Piscataway, NJ) and was used
at 10 l per 1-ml sample. Incubation was for2ha t4 ° Ci nI Pb u f f e ra sf o rt h e
Avidin pulldowns. Immunoprecipitations were as before and used the anti–
PrP-A antibody (Ashok and Hegde, 2008) or 3F4 antibody (Covance). EndoH
and PNGase treatments and analysis of PrP solubility in nondenaturing
detergents was as before (Rane et al., 2004; Ashok and Hegde, 2008; Ashok
and Hegde, 2009). BirA was expressed in E. coli BL21(DE3) pLysS cells with
IPTG (1 mM) induction at midlog phase growth. Expression was for 3 h, after
which the cells were harvested in 300 mM NaCl, 50 mM Tris, pH 8 and lysed
by sonication. The His-tagged BirA was puriﬁed by immobilized Ni2 or
Co2 afﬁnity chromatography (using Chelating-Sepharose from GE), dialyzed
against PBS, and stored in aliquots at 80°C. SDS-PAGE was on 12% Tris-
Tricine gels, except the experiments in Figure 6, which were on 15% Tris-
Tricine gels.
Quantiﬁcation
Autoradiographs were quantiﬁed by phosphorimaging on a Typhoon system,
while images for the ﬁgures were produced by exposure of the same gel to
ﬁlm and scanning in Photoshop. Comparative quantiﬁcation of western blots
were by comparing samples to serial dilutions of standards that were run on
the same blot.
RESULTS AND DISCUSSION
Experimental Strategy
To selectively identify and monitor CtmPrP, we exploited its
unique topology relative to the other PrP forms: cytosoli-
cally exposed N-terminal domain with C-terminal domain
in the ER lumen. Because the C-terminal domain has accep-
tor sites for N-linked glycosylation, its residence in the lu-
men can be readily monitored. To generate a similar topo-
logic marker for the cytosolically exposed N terminus, we
took advantage of orthogonal biotinylation of an artiﬁcial
short sequence by the bacterial BirA biotin ligase (Schatz,
1993). This enzyme, which covalently attaches biotin to its
substrate proteins, has been found by screening and reﬁne-
ment to biotinylate a short artiﬁcial acceptor sequence of 13
residues (Schatz, 1993; Beckett et al., 1999; hereafter termed
the BioTag; see Figure 1A). This BioTag, which contains an
acceptor lysine for biotinylation, is efﬁciently modiﬁed by
BirA, is not found in any natural proteins, and is not recog-
nized by mammalian biotinylating enzymes (Schatz, 1993;
Beckett et al., 1999; Howarth et al., 2005; Kulman et al., 2007).
This makes the BirA-BioTag system orthogonal, allowing
the generation of a highly speciﬁc and easily detectable
modiﬁcation.
We therefore reasoned that PrP BioTagged within its N-
terminal domain could allow selective CtmPrP detection
(Figure 1B). When this Biotagged PrP (PrPBio) is expressed in
cells containing BirA in the cytosol, only CtmPrP should be
both biotinylated and glycosylated. The majority of PrP
would be fully translocated into the ER lumen cotranslation-
ally, thereby escaping biotinylation (but not glycosylation).
By contrast, cytosolic PrP would be biotinylated but not
glycosylated, and NtmPrP would be neither glycosylated nor
biotinylated. Thus, using two topologically restricted mod-
iﬁcations allows, in principle, the four potential forms of PrP
to be discriminated (Figure 1B). In practice however, any
potential inefﬁciencies in the modiﬁcation reactions could
make the lack of a modiﬁcation difﬁcult to interpret with
certainty, especially when dealing with low abundance spe-
cies. For this reason, and because of its clear physiological
importance, we focused on CtmPrP, whose double modiﬁca-
tion can be interpreted with a high degree of conﬁdence.
Our overall strategy was to develop and validate this
compartment-restricted tagging strategy in vitro and in cells
using variants of PrP with well-deﬁned and uniform (or
nearly uniform) topology. Once validated, we sought to then
apply the method to wild-type PrP so that basic but critical
unanswered questions about CtmPrP could be addressed.
And ﬁnally, we investigated whether inherited mutants in
human PrP that cause neurodegeneration might inﬂuence
CtmPrP metabolism.
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The 13-residue BioTag, with a ﬂanking Alanine on either
side, was inserted into PrP at codon 50, between the ﬂexible
N-terminal 27 residues and the octarepeat region. Insertion
of a short tag in this region is not expected to have any effect
on PrP based on earlier studies inserting either an epitope
tag or GFP (Negro et al., 2001; Lorenz et al., 2002; Chakrabarti
and Hegde, 2009; Ashok and Hegde, 2009). Thus, through-
out this study, all constructs were modiﬁed at this site and
the modiﬁed constructs indicated by a superscript ‘Bio’ (or
‘HA’ for the HA epitope tag) in the name. Two versions of
PrP that are uniformly (or very nearly so) in the CtmPrP or
fully translocated topologic forms were BioTagged and
tested in an in vitro system (Figure 2A).
As characterized before (Chakrabarti and Hegde, 2009),
SA-PrPBio translated in rabbit reticulocyte lysate in the pres-
ence of canine pancreatic rough microsomes was inserted
efﬁciently into the membrane as judged by its glycosylation,
cosedimentation with microsomes, protease accessibility of
its N terminus, and protease protection of its C terminus. By
contrast, Prl-PrP(G123P)Bio (containing the highly efﬁcient
signal sequence from Prolactin fused to PrP with a Gly to
Pro change in the potential membrane-spanning region) was
fully translocated into the lumen based on its glycosylation
and complete protection from protease digestion (Figure
2A). These two constructs therefore serve as the two ex-
tremes in topology, representing the greatest and least
amount of CtmPrP possible.
When these translation products were incubated with re-
combinant BirA, SA-PrP Bio but not Prl-PrP(G123P) Bio could
be efﬁciently recovered with immobilized Avidin (Figure
2A). Importantly, capture with Avidin was dependent on
adding BirA, required the BioTag, and could be competed
by excess biotin (Figure 2B and unpublished data). Thus,
BirA-dependent biotinylation of the BioTag can occur on
CtmPrP, and this product could be selectively captured with
immobilized Avidin. Quantiﬁcation showed that if the ex-
tent of SA-PrP Bio capture by Avidin was deﬁned as 100%,
capture of Prl-PrP(G123P) Bio was 3%. Because this was
roughly the same amount of translation product recovered
in the absence of BirA, it presumably represents the back-
ground of this assay generated by low level nonspeciﬁc
sticking of PrP to the Avidin resin. Relative to these stan-
dards, wild-type PrPBio showed 13% biotinylation of the
glycosylated product, consistent with the fact that 16% of
this band was found to be in the CtmPrP form by protease-
protection assays (Figure 2, C and D). Importantly,
PrP(AV3)Bio and PrP(G123P)Bio, mutants that respectively
increase and decrease CtmPrP generation (Hegde et al., 1998),
led to corresponding changes in biotinylation (Figure 2, C
and D). Thus, biotinylation of the BioTag by cytosolic BirA,
when combined with glycosylation, can be used as a speciﬁc,
sensitive, and quantitative topologic reporter of CtmPrP.
Analysis of Compartment-Restricted Biotinylation
in Vivo
To evaluate the suitability of using biotinylation as a means
to detect CtmPrP in vivo, we coexpressed SA-PrPBio with
BirA in N2a cells and analyzed total cell lysates for biotin-
ylated products by blotting with Avidin-HRP. In prelimi-
nary experiments, we initially conﬁrmed that cells express-
ing BirA without a BioTagged construct, or a BioTagged
construct without BirA, showed the same weakly staining
bands as observed in GFP-transfected control cells (data not
shown). This indicated that BirA has no detectable targets
endogenous to mammalian cells, and that the BioTag is not
modiﬁed by endogenous enzymes. Similar results were seen
in multiple cell types (data not shown), where the main
endogenous products detected by Avidin-HRP were two
high molecular weight bands characterized before as mito-
chondrial biotin-containing enzymes (Howarth et al., 2005).
When SA-PrPBio was introduced into BirA-expressing
cells, it was clearly visualized on blots with both anti-PrP
antibodies and Avidin-HRP (Figure 3A). SA-PrP biotinyla-
tion was entirely dependent on the BioTag, because SA-PrP
lacking the BioTag was not detected by Avidin-HRP despite
expression at high levels as judged by its detection with
anti-PrP. The presence of biotin in the media maximized
biotinylation of SA-PrPBio, but was not absolutely required
(Figure 3B). Presumably, low level biotin in the serum and
endogenous cellular biotin pools are sufﬁcient. The biotin-
ylated SA-PrPBio was conﬁrmed to be glycosylated by its
recovery with immobilized ConA (Figure 3A). Controls with
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Figure 1. Experimental strategy for compartment-
restricted biotinylation. (A) Diagram of PrP (top)
and SA-PrP (bottom) indicating key elements: SS –
signal sequence; HD – hydrophobic domain; CHO –
glycosylation site; GPI – signal for glycosylphosphati-
dylinositol anchor attachment; SA – signal anchor
(from Asialoglycoprotein receptor). In addition, the
BioTag and control HA sequences are shown at their
site of insertion. The Lysine that becomes biotinyl-
ated is in red. SA-PrP lacks an N-terminal signal
sequence and is instead targeted to and inserted via
the SA domain. The ﬂanking charges ensure its type
II orientation, resulting in the C terminus being
translocated into the ER lumen. Numbering is for
Human PrP. (B) Diagram of the four potential topo-
logic forms that can be achieved by PrP, with the
glycans indicated in green, and the BioTag in red.
On introduction of BirA to the cytosol, cyPrP and
CtmPrP become biotinylated (‘B’). A chart summariz-
ing the modiﬁcations is shown.
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speciﬁcity of ConA binding under the conditions used in
this study (Supplemental Figure S2). Furthermore, blotting
of lysates before and after incubation with immobilized
Avidin illustrated that most of the SA-PrPBio was biotin-
ylated (Figure 3C). The residual amount remaining in the
unbound fraction was likely due to inefﬁciency in Avidin
binding using batch-pulldown. Thus, a construct expected
to be in the CtmPrP form can be site-speciﬁcally and efﬁ-
ciently biotinylated in vivo with cytosolic BirA. That this
biotinylated species is also glycosylated conﬁrms its Ctm-
PrP topology.
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Figure 2. Biotinylation assay for PrP topology
in vitro. (A) SA-PrPBio and Prl-PrP(G123P)Bio
were in vitro translated and inserted into ER-
derived microsomes using reticulocyte lysate
and pancreatic microsomes. After translation,
the samples were incubated for1ho ni c ewith
BirA and subjected to proteinase K (PK) diges-
tion, sedimentation to isolate the microsomes,
and/or pulldown using immobilized Avidin as
indicated. The products were analyzed by SDS-
PAGE and autoradiography. The positions of
PrP containing 0, 1, or 2 glycans (CHO) are
indicated. The double and single asterisks indi-
cates the positions of glycosylated and ungly-
cosylated C-terminal fragments generated by
partial PK digestion of CtmPrP (Hegde et al.,
1998). Note that SA-PrPBio is quantitatively in
the CtmPrP topology as judged by PK digestion,
and is efﬁciently biotinylated as judged by Avi-
din-pulldown. By contrast, Prl-PrP(G123P)Bio is
quantitatively PK-protected, and fails to be bi-
otinylated by BirA, both indicative of its com-
plete translocation into the lumen of the micro-
somes. (B) Biotinylation reactions of in vitro
translated and membrane inserted SA-PrPBio at
various temperatures for 30 min, followed by
Avidin-pulldowns as in panel A. (C) PK diges-
tion and biotinylation assays for PrPBio,
PrP(AV3)Bio, and PrP(G123P)Bio as in panel A.
(D) Quantiﬁcation of results from panels A and C. Plotted are the proportions of fully glycosylated PrP that is PK-accessible (black bars), or
that is recovered by immobilized Avidin (gray bars), both of which are indicators of CtmPrP.
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Figure 3. Biotinylation assay for PrP topology
in vivo. (A) SA-PrP and SS-PrP lacking or
containing the BioTag were transfected into
BirA-expressing N2a cells and analyzed 24 h
later. Total cell lysates or ConA-bound prod-
ucts were separated by SDS-PAGE, blotted,
and probed with either anti-PrP antibodies (-
PrP) or Avidin-HRP as indicated. Note that low
levels of endogenous PrP are visualized at 35
kDa in the SS-PrP samples probed with
-PrP. (B) SA-PrPBio was transfected into N2a
cells expressing or lacking BirA and cultured in
the indicated concentrations of biotin for 24 h.
Total cell lysates were analyzed for biotinyl-
ated products by blotting with Avidin-HRP.
(C) N2a cells expressing BirA were transfected
with either a GFP-expressing plasmid (control),
SA-PrP, or SA-PrPBio. Total cell lysates were
incubated with immobilized Avidin to pull-
down the biotinylated proteins. Samples of the
total lysate, unbound fraction, and bound frac-
tion were analyzed by immunoblotting with
anti-PrP. (D) The indicated constructs were
transfected into N2a cells expressing either cy-
tosolic BirA or SS-BirA-KDEL (ER-BirA). Total
cell lysates were analyzed by blotting and
probed for either total PrP (-PrP) or biotinyl-
ated products (with Avidin-HRP). ‘2HA’ indi-
cates a construct containing two tandem HA
tags.
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ER targeting signal (SS-PrPBio) was also biotinylated by
BirA in a BioTag-dependent manner (Figure 3A). This is
noteworthy because nontargeted cytosolic PrP is rapidly
degraded, and the ability to detect its biotinylation illus-
trates that even short-lived species that are likely chaperone-
associated can be tagged by BirA.
We also examined the consequences of directing BirA to
the ER lumen with an N-terminal signal sequence and C-
terminal KDEL sequence (SS-BirA-KDEL). In principle, this
should preclude biotinylation of a cytosolically exposed Bio-
Tag, while permitting biotinylation of a BioTag in the ER
lumen. As expected, biotinylation of SA-PrPBio was clearly
decreased (Figure 3D). In contrast, wild-type PrPBio, the
majority of which is expected to be translocated completely
into the ER lumen, was biotinylated to a greater extent by
ER-targeted BirA than by cytosolic BirA (Figure 3D). While
generally consistent with expectations, biotinylated and gly-
cosylated SA-PrPBio was still detectable in cells expressing
SS-BirA-KDEL. This could be due to either residual SS-BirA-
KDEL in the cytosol (i.e., due to translocation inefﬁciency),
small amounts of SA-PrPBio being fully translocated into the
ER lumen, or post-lysis biotinylation.
We favor the ﬁrst explanation for two reasons. First, sen-
sitive reporter assays have previously shown that signal-
containing proteins are never translocated with complete
efﬁciency, leaving at least a few percent in the cytosol (Le-
vine et al., 2005). Second, mixing experiments of cell lysates
from BirA-expressing cells with lysates from PrPBio-express-
ing cells showed no detectable post-lysis biotinylation under
either the denaturing or nondenaturing lysis conditions we
used (Supplemental Figure S3). This is presumably because
upon washing and lysis of the cells, the concentrations of
BirA, substrate, and biotin are reduced many orders of mag-
nitude below their cellular levels, making the reaction very
inefﬁcient even if nondenaturing conditions are used. Thus,
we conclude that while the majority of SS-BirA-KDEL is
translocated and resides in the ER lumen [where it is appar-
ently quite active, as observed before (Mize et al., 2008)],
sufﬁcient amounts of it are mislocalized to the cytosol where
it can partially biotinylate a cytosolically exposed BioTag.
Because SS-BirA-KDEL does not represent an absolute com-
partment-restricted enzyme, we focused the remainder of
our efforts on using cytosolic BirA.
Detection of CtmPrP Generated by Wild-Type PrP
The SA-PrP model protein illustrated that biotinylation com-
bined with glycosylation provides a rigorous means to de-
tect CtmPrP since each modiﬁcation is strictly restricted to
different compartments. We sought to apply this method to
unambiguously address whether CtmPrP is a normal prod-
uct of wild type PrP biosynthesis. Although CtmPrP is gen-
erated from wild-type PrP in vitro, it is a minor product that
some have argued represents inefﬁciencies or mistakes of an
in vitro reaction comprising heterologous components (such
as reticulocyte lysate and microsomes from pancreas).
Whether CtmPrP is generated in vivo has been debatable
because the assays for its detection have limited sensitivity
and rely on either cumbersome biochemical fractionation
(such as isolation of microsomes) or relatively crude limited
protease digestion assays.
To address this issue, PrPBio was coexpressed with cyto-
solic BirA, and the products were analyzed by various meth-
ods. PrP, whether it contains or lacks the BioTag, is ex-
pressed as a heterogeneously glycosylated set of products,
with a small amount of unglycosylated material (Figure 4A).
Detection of the biotinylated species with Avidin-HRP
showed several BioTag-dependent PrP species (Figure 4A).
The smallest of these products comigrated with unglycosy-
lated PrP and was veriﬁed as such by its lack of binding to
immobilized ConA. Furthermore, this band was the most
efﬁciently biotinylated PrP product relative to its abundance
in the total PrP blot, suggesting a high degree of cytosolic
exposure. These observations suggest this species represents
cyPrP, although it may also include CtmPrP that failed to
receive N-linked glycans. Among glycosylated PrP species, a
small proportion (5–10%) was detected with Avidin-HRP.
Most of these products could be pulled down with immo-
bilized ConA and visualized by Avidin-HRP, conﬁrming its
dual modiﬁcation with biotin and N-glycan, consistent with
the CtmPrP topology.
In addition to detection of steady state levels of biotinyl-
ated PrP species, we could also selectively recover these
forms from pulse-labeled cells (Figure 4B). As with the
steady state analysis, capture of pulse-labeled PrP with im-
mobilized Avidin was dependent on the BioTag. The assign-
ment of bands as glycosylated and unglycosylated products
was again conﬁrmed using ConA binding (Figure 4C). Com-
paring the total pulse-labeled PrPBio (recovered using anti-
PrP immunoprecipitation) to that recovered with immobi-
lized Avidin showed that unglycosylated PrPBio was
biotinylated to higher speciﬁc activity than glycosylated
PrPBio. Relative to glycosylated SA-PrPBio, glycosylated PrPBio
was biotinylated to 10-fold lower levels. Given that SA-PrPBio
is uniformly in the CtmPrP topology, this indicates that only a
small proportion of glycosylated PrPBio is represented by
CtmPrP (10% in this experiment). Although the precise
proportion of PrPBio in the CtmPrP topology varied depend-
ing on cell culture conditions, cell type, expression level,
labeling time, and other parameters yet to be delineated, it
was always many-fold lower than SA-PrP and was always a
detectable but minor proportion of total synthesized PrP.
These observations are consistent with unglycosylated PrP-
Bio representing primarily cytosolic species, while the glyco-
sylated PrPBio represents a mixture of fully translocated
species with minor amounts of CtmPrP.
To further validate this conclusion, we tested whether
biotinylation could be decreased by two independent ma-
nipulations that each reduce CtmPrP production. In the ﬁrst
strategy, we replaced the PrP signal sequence with that from
Prolactin (Prl). Earlier studies have shown that both CtmPrP
and cyPrP are dependent on slight inefﬁciency of the native
PrP signal sequence, and that both can be reduced (although
not completely eliminated) by the more efﬁcient Prl signal
(Kim and Hegde, 2002; Rane et al., 2004; Kang et al., 2006;
Rane et al., 2010). Indeed, relative to PrPBio, Prl-PrPBio was
reduced in the amount of both glycosylated and unglycosy-
lated biotinylated PrP products recovered from pulse-la-
beled cells (Figure 4D). When total cell lysates were ana-
lyzed by blotting with Avidin-HRP, Prl-PrPBio again showed
a substantially reduced biotinylated population compared
with PrPBio despite equal or higher overall expression levels
(Figure 4E).
In the second strategy, we analyzed PrP(G123P)Bio, which
reduces CtmPrP levels by altering the potential membrane
spanning region (e.g., Figure 2, C and D and Hegde et al.,
1998). As with Prl-PrPBio, we found that biotinylation of
PrP(G123P)Bio was reduced approximately threefold, very
close to the limits of reliable detection above background.
The reduced biotinylation seen with PrP(G123P)Bio is note-
worthy because it indicates that little if any biotinylation is
occurring during cotranslational protein targeting. If this
were the primary source of biotinylated product, PrPBio and
PrP(G123P)Bio would have been biotinylated equally since
A. B. Emerman et al.
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with identical kinetics.
Three additional points argue against cotranslational bioti-
nylation. First, SRP binds to the signal sequence immediately
after its emergence from the ribosome (Krieg et al., 1986;
Kurzchalia et al., 1986), even before the BioTag is exposed,
thereby initiating the targeting process before the BioTag is
available for modiﬁcation. Second, earlier work in vitro and
in vivo suggests that after the signal emerges from the
ribosome, targeting occurs before even 30 additional resi-
dues are synthesized (Jungnickel and Rapoport, 1995; Goder
et al., 2000). During this period in PrP translation, the BioTag
would reside inside the ribosomal tunnel, where it cannot be
accessed by the large 40 kDa BirA enzyme. Third, even if
targeting were delayed, steric hindrance by the ribosome
and SRP would likely preclude efﬁcient access to the nascent
PrP by BirA. For these reasons, both experimental and the-
oretical, we believe that biotinylation represents a post-
translational event that is reporting on the ﬁnal topologic
location of the BioTag.
Thus, on the basis of dual modiﬁcation by two topologi-
cally restricted enzymes (BirA and Oligosaccharyl trans-
ferase) and the results of various mutants that inﬂuence PrP
topology [SA-PrP, SS-PrP, Prl-PrP, and PrP(G123P)], we
conclude that biotinylated and glycosylated PrPBio repre-
sents CtmPrP. While unglycosylated biotinylated PrP clearly
includes cyPrP, it may well be a mixture with CtmPrP that
failed to be glycosylated. Our ability to detect CtmPrP gen-
erated by wild-type PrP with high speciﬁcity at both steady
state and by pulse-labeling paved the way to an analysis of
this pathologically important form of PrP.
Characterization of CtmPrP Trafﬁcking and Metabolism
With this assay for CtmPrP in hand, we addressed several
basic, but still unresolved, questions regarding its normal
biosynthesis and metabolism. Earlier studies using highly
CtmPrP-favoring mutants [such SA-PrP or L9R-PrP(AV3)]
have come to conﬂicting conclusions about the metabolism
and cellular location of CtmPrP, ranging from ER, Golgi, or
various other parts of the secretory pathway (Hegde et al.,
1998; Stewart et al., 2001; Stewart and Harris, 2005;
Chakrabarti and Hegde, 2009). However, these mutants are
rather substantially modiﬁed, and it is unclear whether con-
clusions derived from them are entirely applicable. Whether
CtmPrP generated from wild-type PrP ever leaves the ER,
and if it does, whether it samples the cell surface, is un-
known.
We found that the majority of biotinylated glycosylated
PrPBio (i.e., CtmPrP) was sensitive to endoglycosidase H
(EndoH) digestion (Figure 5A), indicating that most glycans
on CtmPrP have not been processed by Golgi enzymes. How-
ever, a small amount of more slowly migrating bands was
consistently observed, and these species were resistant to
EndoH digestion, only being deglycosylated with PNGase F.
The same species was also found to be accessible to extra-
cellular trypsin, while the majority of biotinylated PrP was
inaccessible (Figure 5B). When total PrP in the same samples
was analyzed by blotting for PrP, the majority of PrP was
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Figure 4. The biotinylation assay reveals CtmPrP generated by wild-type PrP. (A) Wild-type Human PrP constructs lacking or containing
the BioTag were transfected into BirA-expressing N2a cells and analyzed 24 h later. Total cell lysates or ConA-bound products were separated
by SDS-PAGE, blotted, and probed with either anti-PrP antibodies (-PrP) or Avidin-HRP as indicated. The positions of glycosylated
(CHO) and unglycosylated (-CHO) PrP are indicated. (B) The indicated constructs were transfected into BirA-expressing N2a cells and the
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with immobilized Avidin, and the products visualized by SDS-PAGE and autoradiography. (C) An experiment as in panel B, except that the
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B). These observations indicate that in contrast to the major
population of PrP, which is at the cell surface, CtmPrP is
primarily intracellular, possibly in the ER as judged by its
EndoH-sensitive glycans. However, at least some CtmPrP
clearly leaves the ER and goes to the cell surface as evi-
denced by an EndoH-resistant population accessible to ex-
tracellular trypsin.
We also noticed in the course of our studies that CtmPrP
was more difﬁcult to solubilize in nondenaturing detergents
than non-Ctm forms (unpublished observations; see also
Figure 7A below). While insolubility could mean aggrega-
tion, we do not believe this to be the case because aggregates
of a membrane protein would be unlikely to trafﬁc through
the secretory pathway and be modiﬁed on its glycans en
route. Rather, it seems that two modes of membrane anchor-
ing on the same molecule (via a transmembrane segment
and GPI anchor) make it more difﬁcult to solubilize. Regard-
less of the reason, this observation provides a further point
of distinction between CtmPrP and the major PrP species. It
also emphasizes the need to use efﬁcient solubilization
methods (e.g., SDS) to avoid losing subpopulations of PrP in
any biochemical analyses. Indeed, standard lysis buffer con-
ditions are insufﬁcient to recover CtmPrP, perhaps explaining
some of the earlier conﬂicting reports on its properties. Thus,
unless speciﬁcally used for fractionation purposes, all of our
experiments were harvested and solubilized in boiling SDS
before further analysis to ensure complete recovery of all
PrP species.
Using pulse-chase analysis combined with Avidin pull-
downs, we estimated the half-life of CtmPrP as being 5–7 h
(Figure 5C). Consistent with the steady state analysis, most
PrP synthesized during the pulse-labeling subsequently ma-
tured to heterogeneous complex glycosylated forms, after
which it was degraded. By contrast, the majority of CtmPrP
remained core-glycosylated. By the pulse-chase method, we
found it difﬁcult to reliably detect a biotinylated complex
glycosylated species due to a low signal from this diffuse
band relative to background. However, the steady state
analysis does indicate that some proportion of CtmPrP does
undergo complex glycan modiﬁcation and trafﬁc to the cell
surface (Figure 5, A and B). It is worth noting that although
most of CtmPrP remains core-glycosylated, its residence in
the ER cannot be assumed because glycoproteins can be
trafﬁcked through the Golgi without necessarily obtaining
further glycan modiﬁcations. At this point, we do not know
the full itinerary of CtmPrP trafﬁcking, although it does ap-
pear to sample much of the secretory and endocytic path-
ways given its eventual degradation in the lysosome (see
below).
We used inhibitors to assess the normal degradation path-
way used by CtmPrP. We focused on the ratio of glycosylated
biotinylated products (i.e., CtmPrP) to unglycosylated biotin-
ylated PrP (i.e., primarily cyPrP), because the latter is well
established to be degraded by the proteasome. Relative to
untreated cells (where the CtmPrP and cyPrP bands are
roughly equal at steady state), proteasome inhibition (with
either MG132 or Lactacystin) clearly results in cyPrP levels
exceeding CtmPrP (Figure 5D). By contrast, lysosomal inhi-
bition with either Baﬁlomycin A1 or Leupeptin resulted in
increased CtmPrP relative to cyPrP (Figure 5D). These results
indicate that while cyPrP is primarily degraded by a protea-
some-dependent pathway, CtmPrP is primarily degraded in
lysosomes.
And ﬁnally, we wished to assess the status of signal
sequence processing on CtmPrP. Although a seemingly eso-
teric point, this issue is important for two reasons. First, it is
quite unusual for a signal sequence containing protein to be
generated in a topology where the N terminus is cytosolic.
This necessarily means that the polypeptide segment down-
stream of the signal sequence has failed to be translocated
into the ER, a fate inconsistent with signal sequence func-
tion. The step at which this fails in vivo has been unclear. If
it fails at the step of targeting to or initial gating of the
AB
CD
α-PrP IPs Avidin pulldowns
2xCHO
1xCHO
0xCHO
complex 2xCHO
1xCHO
0xCHO
complex
nothing
DMSO
MG132
Baf1A
Lact.
Leupep.
Avidin pulldown -> α-PrP blot
chase(h): 0 .5 1 2.5 5 7 0 .5 1 2.5 5 7
100 92 97 68 53 48 % remaining:
2xCHO
1xCHO
0xCHO
complex
α-PrP
Avidin
untreated
trypsin
untreated
trypsin
Total
Blot: α-PrP
Lysate:
2xCHO
1xCHO
0xCHO
complex
Avidin
α-TRAPα
untreated
EndoH
PNGaseF
untreated
EndoH
PNGaseF
untreated
EndoH
PNGaseF
Total
α-PrP
Total
Blot:
Lysate:
α-PrP
Figure 5. Analysis of CtmPrP metabolism.
(A) Cells expressing wild-type PrPBio and
BirA were either left untreated or digested
with extracellular trypsin. After washing and
collecting the intact cells, they were harvested
and either analyzed directly, or after capture
of biotinylated products with immobilized
Avidin. The blot was probed with anti-PrP
antibodies. (B) Total lysates from cells ex-
pressing PrPBio and BirA were either left un-
treated or digested with Endoglycosidase H
or PNGase F as indicated. The samples were
then analyzed directly or after capture of bi-
otinylated products with immobilized Avi-
din. The blot was probed with anti-PrP anti-
bodies to visualize PrP, or anti–TRAP,a n
ER-resident glycoprotein that serves as a con-
trol for the glycosidase digestions. (C) Cells
expressing PrPBio and BirA were pulse la-
beled with [35S]methionine for 30 min and
chased with unlabeled media for the indi-
cated times. Lysates harvested at each time
point were divided in half and immunopre-
cipitated with anti-PrP or pulled down with
immobilized Avidin. The percent of glycosy-
lated biotinylated PrP species remaining at
each time point was quantiﬁed by phospho-
rimaging and indicated above the respective
lanes. (D) Cells expressing PrPBio and BirA were treated for 16 h with the indicated compounds: 10 uM MG132, 250 nM Baﬁlomycin 1A, 5
uM Lactacystin, or 0.2 mM Leupeptin. DMSO served as a vehicle control. Total cell lysates were subjected to Avidin pulldowns and the
biotinylated products visualized with anti-PrP immunoblotting.
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However, slippage of the polypeptide after initiating trans-
location could result in signal cleavage if it has transiently
accessed the ER lumen where the signal peptidase active site
resides. The second reason for assessing this is that because
the signal sequence is hydrophobic, its lack of processing on
CtmPrP would generate a domain that may be prone to
aggregation and/or inappropriate interactions that could
play a role in cellular dysfunction caused by CtmPrP. While
analysis of a CtmPrP-favoring mutant showed lack of signal
sequence processing (Stewart et al., 2001), this construct
contains a mutation in the signal sequence itself that may
have affected the results.
To address this issue, we initially isolated CtmPrP on the
basis of its glycosylation and biotinylation and analyzed its
migration relative to signal cleaved and uncleaved stan-
dards (data not shown). However, interpretation of this
result proved more complicated than expected because of
uncertainties about the effect of GPI anchor processing and
deglycosylation (which converts Asparagines to Aspartates)
on migration. To avoid these complications, we introduced a
TEV cleavage site in the N-terminal domain downstream of
the BioTag. After binding the glycoproteins (which would
include CtmPrP) to immobilized ConA, the N-terminal do-
main of PrPBio/TEV was liberated by digestion with TEV and
the biotinylated N terminus (which necessarily is from Ctm-
PrP) was puriﬁed with immobilized Avidin (Figure 6A).
This short product was then compared with signal-con-
taining and signal-lacking versions of the fragment gen-
erated in vitro.
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diography. Note that no digestion occurs in the absence of the TEV site, while all of the PrP products are digested efﬁciently by TEV. PrP
is barely visible in the ConA-selected products, which contains many endogenous cellular glycoproteins. Analysis was on 15% Tricine gels
to maximize separation of small products. (C) Samples treated as in panel B were further selected by Avidin pulldowns and visualized by
autoradiography. Markers for PrP from residue 1 up to the TEV site (SS) or residue 23 up to the TEV site (SS) were produced by in vitro
translation and analyzed on the same gel. Note that an unidentiﬁed background translation product was seen in both samples (asterisks). The
source of this product is unknown, although the nuclease digested translation system likely contains numerous mRNA fragments, some of
which may be translated to generate small truncated products not normally visualized at the bottom of a gel. Analysis of this experiment was
on 15% Tricine gels.
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ciently cleave immobilized PrP on beads. To do this, PrP was
immunoprecipitated with immobilized antibodies and after
washing, incubated with TEV protease. PrPBio/TEV, but not
PrPBio, was efﬁciently digested to yield the expected cleav-
age products (Figure 6B). Parallel samples on immobilized
ConA also showed evidence that PrPBio/TEV was being di-
gested similarly (Figure 6B). When the released products
from the ConA digestion were further puriﬁed on immobi-
lized Avidin, an 7-kDa band was speciﬁcally recovered in
a TEV protease and PrPBio/TEV dependent manner (Figure
6C). Comparison of this product to in vitro translation prod-
ucts of signal-containing and signal-lacking fragments
showed that the TEV-cleaved product from in vivo gener-
ated CtmPrP comigrates with the signal-lacking marker frag-
ment (Figure 6C). Thus, CtmPrP generated in vivo appears to
have its signal sequence removed, suggesting that it is gen-
erated by slippage of the N terminus out of the translocon at
a step after the polypeptide has transiently accessed the ER
lumen. The absence of this hydrophobic peptide may ex-
plain why CtmPrP is not recognized as a misfolded substrate
for degradation by ER-associated degradation, while earlier
studies generating CtmPrP by mutating the signal sequence
(which precluded its processing) came to different conclu-
sions (Stewart et al., 2001).
A Disease-Causing PrP Mutant that Alters CtmPrP
Metabolism
An increased proportion of PrP is generated in the CtmPrP
form when residues in the central hydrophobic domain
(HD) are mutated to more hydrophobic residues. This in-
cludes artiﬁcial mutants such as PrP(AV3), in which three
alanines are changed to valines, as well as several naturally
occurring disease-associated human PrP mutants (such as
A117V; Hegde et al., 1998; Hegde et al., 1999; Kim et al., 2001;
Stewart and Harris, 2003). Based on analyses of such HD
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Figure 7. A disease-causing PrP mutant selectively alters CtmPrP metabolism. (A) BirA-expressing N2a cells were transfected with either
PrPBio or PrP(H187R)Bio, lysed under nondenaturing conditions (with 0.5% Triton X-100 and 0.5% Deoxycholate), and separated into a
detergent soluble fraction (S) and insoluble pellet (P). The samples were probed with anti-PrP or Avidin-HRP. (B) Total cell lysates in
triplicate expressing BirA and the indicated construct were either immunoprecipitated with anti-PrP and blotted with Avidin-HRP (left) or
pulled down with Avidin and blotted with anti-PrP (right). In both cases, the amount of biotinylated PrP was consistently higher for
PrP(H187R)Bio. (C) BirA-expressing N2a cells were transfected with either PrPBio or PrP(H187R)Bio, pulse-labeled for 30 min, harvested, and
pulled down with Avidin to isolate biotinylated products. The samples were separated by SDS-PAGE and transferred to nitrocellulose
membrane. The membrane was probed with anti-PrP antibodies to detect total biotinylated products (left). After the blot, the membrane was
dried and exposed to x-ray ﬁlm to detect newly synthesized (i.e., radiolabeled) biotinylated products (right). (D) Pulse-chase analysis of PrPBio
and PrP(H187R)Bio. Pulse labeling was for 30 min, and chase was for 7 h. Samples were divided in two and either immunoprecipitated with
anti-PrP or pulled down with immobilized Avidin. (E) PrP(H187R)Bio and Prl-PrP(H187R)Bio were analyzed as in panel A.
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Molecular Biology of the Cell 4334mutants in transgenic mice, increased levels of CtmPrP have
been linked to the development of neurodegeneration
(Hegde et al., 1998; Hegde et al., 1999; Stewart et al., 2005;
Yang et al., 2009; Rane et al., 2010). It is therefore thought that
CtmPrP may contribute to at least some genetic human dis-
ease caused by such PrP mutations in the central HD. How-
ever, numerous PrP mutants lie outside the HD and do not
increase CtmPrP production at the ER as assayed in vitro
(Stewart and Harris, 2001). Indeed, our own in vitro anal-
ysis of two such mutants [PrP(H187R) and PrP(E200K)] by
both protease-protection and biotinylation assays con-
ﬁrmed this conclusion (Supplemental Figure S4). How
such mutations lead to disease is unknown. Given that
CtmPrP is capable of causing disease, we decided to ask
whether in vivo, any of the non-HD mutants might some-
how affect CtmPrP metabolism.
An initial screen using the biotinylation assay of most of
the inherited disease-causing PrP mutants suggested that
several (but not all) mutants have somewhat increased bio-
tinylated products (unpublished observations). Among
these, PrP(H187R) was especially obvious, and we therefore
focused further efforts on this mutant. Our earlier analysis of
PrP(H187R) had shown that relative to wild-type PrP, a
greater proportion of the mutant is detergent insoluble, and
this population is speciﬁcally enriched in immaturely glyco-
sylated, EndoH-sensitive, intracellularly localized species
(Ashok and Hegde, 2009). Because these properties are in
many ways similar to the behavior of CtmPrP (Figure 5), we
asked if the mutant-enriched detergent insoluble fraction
contained CtmPrP as judged using our biotinylation assay.
When PrPBio and PrP(H187R)Bio cell lysates were fraction-
ated on the basis of detergent solubility and probed for
biotinylated species, nearly all of the biotinylated species in
both samples was insoluble, and clearly increased for
PrP(H187R)Bio (Figure 7A). This difference was consistently
seen regardless of how it was visualized: PrP immunopre-
cipitates probed with Avidin-HRP, and Avidin-pulldowns
probed with anti-PrP both showed increased biotinylated
products for PrP(H187R)Bio (Figure 7B). This suggested that
the total amount of CtmPrP (and cyPrP) was greater for
PrP(H187R) than for PrP. Yet, in vitro translocation analysis
of PrP(H187R) did not show increased production of either
CtmPrP or cyPrP (Supplemental Figure S4). To resolve this
discrepancy, we pulse-labeled cells and used Avidin-pull-
downs to visualize the cyPrP and CtmPrP being produced by
PrPBio and PrP(H187R)Bio. An autoradiograph of the pull-
downs showed that both the wild type and mutant generate
comparable amounts of biotinylated species after a 30 min
pulse labeling (Figure 7C). When the exact same samples
were instead blotted with anti-PrP antibodies to visualize
total cellular levels of biotinylated product, PrP(H187R)Bio
clearly had 2–3-fold more than PrPBio. Thus, PrP and
PrP(H187R) produce biotinylated species (i.e., CtmPrP and
cyPrP) at similar rates, consistent with in vitro translocation
analyses; yet, the mutant has higher steady state levels. This
strongly suggested that the turnover of the mutant CtmPrP
and cyPrP is slower compared with wild-type CtmPrP and
cyPrP.
To test this directly, we performed pulse-chase analysis
(Figure 7D). When total PrP was analyzed by anti-PrP im-
munoprecipitation, a subtle difference was observed be-
tween PrPBio and PrP(H187R)Bio wherein some bands were
slightly overrepresented in the chase sample of the mutant
(as has been previously observed; Ashok and Hegde, 2009).
Pulldowns with Avidin of these same samples revealed the
overrepresented species to be biotinylated. While the biotinyl-
ated species were reduced by 50% at the 7 h chase time for
PrPBio, it was hardly diminished (20%) for PrP(H187R)Bio.
Although the absolute amount of biotinylated species varied
somewhat from experiment to experiment, their selective sta-
bilization with the mutant was consistently observed (Supple-
mental Figure S5). Thus, we conclude that the H187R mutation
has the effect of stabilizing the turnover of CtmPrP, and possibly
also cyPrP.
To further validate this conclusion, we asked whether
improving signal sequence efﬁciency, which reduces CtmPrP
generation, would at least partially normalize the steady-
state levels of detergent-insoluble immature species of
PrP(H187R). Indeed, replacement of the PrP signal sequence
with that from Prl did reduce the detergent insoluble, im-
maturely glycosylated species of PrP(H187R), with a corre-
sponding increase in mature glycosylated soluble forms
(Figure 7E). Had these mutant-speciﬁc aberrant species been
generated from fully translocated forms of PrP (e.g., via their
misfolding), it is difﬁcult to see how they could have been
partially rescued by improving signal sequence efﬁciency.
Thus, we conclude that among the aberrant species gen-
erated by PrP(H187R), CtmPrP is likely to be a contributor,
despite the fact that the mutation does not increase CtmPrP
production. Rather, it appears that the mutation selectively
stabilizes, at least partially, the CtmPrP form to increase its
steady state levels and perhaps its trafﬁcking. Given the
association between CtmPrP and neurodegeneration, it is
attractive to speculate that at least one mechanism contrib-
uting to disease caused by these mutants is via increased
levels of CtmPrP, which among other things may titrate
away key cellular factors important for neuronal function
(Chakrabarti and Hegde, 2009).
Although we have not yet done a complete analysis of all
mutants or many cell types, we are able to conﬁrm that the
selective CtmPrP stabilization is seen in other cell types and
for at least one other disease-causing mutation (Supplemen-
tal Figure S6). Hence, in HEK293, we again observed in-
creased biotinylated glycosylated PrP(H187R)Bio. In this
case, the unglycosylated species was not noticeably in-
creased, perhaps because the cytosolic quality control sys-
tems are somewhat different in these cells. In addition to
H187R, another disease-causing mutant, PrP(E200K), also
showed selective increase in glycosylated biotinylated spe-
cies (Supplemental Figure S6). Similar results were obtained
in HeLa and HT1080 cells (data not shown). Thus, mutants
in the PrP C terminus can selectively inﬂuence the metabo-
lism of CtmPrP, resulting in its increased levels at steady
state. Importantly, not all mutations in the C terminus can be
explained by this mechanism. For example, we found that
PrP(V210I) is unchanged in the amount of CtmPrP at steady
state (data not shown), despite the fact that relative to wild
type, a substantial amount of it is immature and detergent
insoluble (Ashok and Hegde, 2009). Thus, there appear to be
multiple effects of mutations in the C-terminal domain, and
the relatively crude parameters of detergent insolubility and
immature glycans cannot be used to equate all of the mu-
tants. However, the more precise compartment-restricted
biotinylation assay for CtmPrP allowed us to reveal a novel
mechanism by which at least some mutants of PrP inﬂuence
its metabolism.
Conclusions
We have illustrated the ability of site-speciﬁc biotinylation to
covalently mark the cytosolically exposed population of a
protein ordinarily directed to the secretory pathway. In the
case of PrP, this method could be combined with an
ER-speciﬁc modiﬁcation (glycosylation) to selectively
identify and track the low-abundance but biologically
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proves upon other methods to detect CtmPrP, which are
either biochemically cumbersome (e.g., topology assays on
ER microsomes) or based on a faulty premise (such as lack of
signal sequence processing). The method is bio-orthogonal,
has a high signal-to-noise, can be readily applied to other
systems, and works in formats that allow both steady state
analysis and pulse-chase studies. While there are endoge-
nous biotinylated proteins, they do not seem to pose a major
source of background in our biochemical assays. Further-
more, it is straightforward to pre-enrich for one’s protein of
interest (e.g., with immunoprecipitation or ConA in the case
of CtmPrP) before detecting biotinylation to markedly im-
prove signal-to-noise. While direct spatial visualization by
ﬂuorescence (e.g., using ﬂuorophore-labeled Avidin on ﬁxed
cells) is also feasible, this remains to be investigated for the
PrP system.
The utility of this method is exempliﬁed by several new
insights into CtmPrP biosynthesis and metabolism. Not only
were we able to directly detect the CtmPrP population of
wild-type PrP, but we also could show that it is a relatively
stable membrane protein that samples much of the secretory
pathway including the cell surface. The ﬁnding that CtmPrP
is not rapidly degraded from the ER is especially notewor-
thy, because it suggests that this species may not be recog-
nized as aberrant by the cellular quality control machinery.
Indeed, the elements involved in CtmPrP production (the
signal sequence and central hydrophobic domain) are highly
conserved, and it is possible that it has a normal function
that remains to be elucidated. In this scenario, only under
conditions of excess production or stabilization in certain
cell types would CtmPrP be detrimental. The ability to set up
a system for selectively isolating this population (e.g., by
ConA followed by Avidin afﬁnity steps) now paves the way
to determining whether its levels vary in vivo in a cell
type–speciﬁc, aging-dependent, or disease-dependent man-
ner in mice engineered to express PrPBio and BirA. That
CtmPrP is degraded in lysosomes may suggest a means by
which accumulation of transmissible prions could lead to
increased CtmPrP (Hegde et al., 1999). In this view, prion
accumulation would lead to lysosomal dysfunction, which
would delay CtmPrP degradation. Being able to follow Ctm-
PrP metabolism should permit this and related hypotheses
to be tested.
At least in cell culture, the ability to readily detect CtmPrP
revealed an unexpected mechanism leading to its increased
levels. Here, mutants in the C-terminal domain of PrP act
preferentially on the CtmPrP form to stabilize it. This ﬁnding
would have been very difﬁcult to obtain by other means
given the rather subtle effect and the difﬁcult biochemical
properties of CtmPrP. Whether this stabilization is due to
increased aggregation, altered trafﬁcking, or another reason
remains to be determined. However, the increase, while
relatively small, is nonetheless likely to be important given
that even small increases in CtmPrP seem to be capable of
causing neurodegeneration in transgenic mouse models
(Hegde et al., 1998; Hegde et al., 1999; Rane et al., 2010).
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